Navidea Biopharmaceuticals (NAVB) Competitors $0.0005 0.00 (0.00%) As of 08/27/2025 10:36 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainSEC FilingsShort InterestTrendsBuy This Stock NAVB vs. SMFL, VRPX, SCPS, VAXX, ARDS, EVLO, CMRA, GNCAQ, GNCA, and STABShould you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include Smart for Life (SMFL), Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Aridis Pharmaceuticals (ARDS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), and Statera Biopharma (STAB). These companies are all part of the "pharmaceutical products" industry. Navidea Biopharmaceuticals vs. Its Competitors Smart for Life Virpax Pharmaceuticals Scopus BioPharma Vaxxinity Aridis Pharmaceuticals Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Statera Biopharma Navidea Biopharmaceuticals (NYSE:NAVB) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends. Does the media refer more to NAVB or SMFL? In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score. Company Overall Sentiment Navidea Biopharmaceuticals Neutral Smart for Life Neutral Is NAVB or SMFL more profitable? Company Net Margins Return on Equity Return on Assets Navidea BiopharmaceuticalsN/A N/A N/A Smart for Life N/A N/A N/A Which has higher valuation & earnings, NAVB or SMFL? Navidea Biopharmaceuticals has higher earnings, but lower revenue than Smart for Life. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNavidea Biopharmaceuticals$8.13K6.16-$15.18MN/AN/ASmart for Life$11.11M0.00-$22.68MN/AN/A Do institutionals & insiders have more ownership in NAVB or SMFL? 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 31.7% of Smart for Life shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, NAVB or SMFL? Navidea Biopharmaceuticals has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, Smart for Life has a beta of 17.05, meaning that its share price is 1,605% more volatile than the S&P 500. SummaryNavidea Biopharmaceuticals and Smart for Life tied by winning 3 of the 6 factors compared between the two stocks. Get Navidea Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAVB vs. The Competition Export to ExcelMetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$50K$18.05M$5.78B$21.32BDividend YieldN/AN/A3.95%3.51%P/E RatioN/AN/A31.2629.34Price / Sales6.1620.01465.8752.89Price / CashN/AN/A37.7323.86Price / BookN/A0.0110.045.39Net Income-$15.18M-$15.34M$3.27B$996.59M7 Day PerformanceN/A-3.61%3.17%3.12%1 Month PerformanceN/A-10.12%4.34%2.97%1 Year PerformanceN/A-5.19%44.12%12.83% Navidea Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-50.0%$50K$8.13K0.0010SMFLSmart for LifeN/A$0.01+96.2%N/A-100.0%$36K$11.11M0.00110VRPXVirpax PharmaceuticalsN/A$0.01flatN/A-99.9%$14KN/A0.007SCPSScopus BioPharmaN/A$0.00flatN/A+66.7%$13KN/A0.009VAXXVaxxinityN/A$0.00-99.8%N/A-70.0%$13KN/A0.0090Gap DownARDSAridis PharmaceuticalsN/A$0.00+100.0%N/AN/A$11KN/A0.0030Gap UpEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070High Trading VolumeGNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070STABStatera BiopharmaN/A$0.00flatN/A-66.7%$5KN/A0.0020 Related Companies and Tools Related Companies Smart for Life Competitors Virpax Pharmaceuticals Competitors Scopus BioPharma Competitors Vaxxinity Competitors Aridis Pharmaceuticals Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Statera Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NAVB) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access